Clinical Coagulation, Malmö
301 – 400 of 629
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Increased burden on caregivers of having a child with haemophilia complicated by inhibitors.
2013) In Pediatric Blood & Cancer(
- Contribution to journal › Article
-
Mark
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
(
- Contribution to journal › Article
-
Mark
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy.
(
- Contribution to journal › Article
-
Mark
Somatosensory Sensitivity in Patients With Persistent Idiopathic Orofacial Pain Is Associated With Pain Relief From Hypnosis and Relaxation.
(
- Contribution to journal › Article
-
Mark
Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)
(
- Contribution to journal › Article
-
Mark
APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia.
(
- Contribution to journal › Article
-
Mark
Thrombosis in patients with hemorrhagic disorders.
(
- Contribution to journal › Article
-
Mark
Platelet count kinetics following Interruption of antiretroviral treatment: Results from the SMART study.
(
- Contribution to journal › Article
-
Mark
Socioeconomic factors and concomitant diseases are related to the risk for venous thromboembolism during long time follow-up.
(
- Contribution to journal › Article
-
Mark
Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients: The GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
(
- Contribution to journal › Article
-
Mark
Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin.
(
- Contribution to journal › Article
-
Mark
Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic suggestions are performing better than manually changed doses
(
- Contribution to journal › Article
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Article
-
Mark
Dabigatran in clinical practice - One-year experience at Skåne University Hospital.
(
- Contribution to journal › Letter
-
Mark
Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.
(
- Contribution to journal › Article
-
Mark
History of prophylaxis.
(
- Contribution to journal › Article
-
Mark
Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.
(
- Contribution to journal › Article
-
Mark
Intermediate- dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
(
- Contribution to journal › Article
-
Mark
Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden.
(
- Contribution to journal › Article
- 2012
-
Mark
Arterial Thrombosis in Factor V Leiden or Activated Protein C Resistance. Clinical and Experimental Studies.
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Mortality and Inherited Thrombophilia: results from the European Prospective Cohort on Thrombophilia (EPCOT).
(
- Contribution to journal › Article
-
Mark
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
(
- Contribution to journal › Scientific review
-
Mark
Differences between developed and developing countries in paediatric care in haemophilia
(
- Contribution to journal › Article
-
Mark
Quality of life in adult patients with haemophilia - a single centre experience from Sweden.
(
- Contribution to journal › Article
-
Mark
Management of bleeding disorders in children
(
- Contribution to journal › Scientific review
-
Mark
Evaluation of recurrent venous thromboembolism in patients with Factor V Leiden mutation in heterozygous form.
(
- Contribution to journal › Article
-
Mark
Computerised assistance for warfarin dosage - Effects on treatment quality
(
- Contribution to journal › Article
-
Mark
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)
(
- Contribution to journal › Article
-
Mark
Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
(
- Contribution to journal › Letter
-
Mark
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
(
- Contribution to journal › Article
-
Mark
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry
(
- Contribution to journal › Article
-
Mark
The international factor IX treatment network survey.
(
- Contribution to journal › Letter
-
Mark
Von Willebrand disease.
2012) In Pediatric Blood & Cancer(
- Contribution to journal › Article
-
Mark
Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
2012) In Haemophilia(
- Contribution to journal › Article
-
Mark
von Willebrand's disease: a report from a meeting in the Åland islands.
(
- Contribution to journal › Article
-
Mark
Models of prophylaxis.
(
- Contribution to journal › Article
-
Mark
New treatments in hemophilia: insights for the clinician.
(
- Contribution to journal › Article
-
Mark
Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
(
- Contribution to journal › Article
-
Mark
Clinical trial design in haemophilia.
(
- Contribution to journal › Article
-
Mark
Malignant disease in the haemophilic population: moving towards a management consensus?
(
- Contribution to journal › Article
-
Mark
Modern haemophilia care.
(
- Contribution to journal › Article
-
Mark
Prevention and prediction of inhibitor risk.
(
- Contribution to journal › Article
-
Mark
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
(
- Contribution to journal › Article
-
Mark
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
(
- Contribution to journal › Article
-
Mark
Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
(
- Contribution to journal › Article
-
Mark
The Arosenius Fund.
(
- Contribution to journal › Article
- 2011
-
Mark
Risk factors for hemorrhage during local intra-arterial thrombolysis for lower limb ischaemia
(
- Contribution to journal › Article
-
Mark
Inhibitors in haemophilia A - Prevention, current management and personalised therapy perspectives
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Bone Mineral Density in Haemophilila: A Treatment Outcome
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
(
- Contribution to journal › Article
-
Mark
Inhibitors in haemophilia A - Prevention, current management and personalised therapy perspectives
(
- Contribution to journal › Article
-
Mark
The international factor IX treatment network survey
(
- Contribution to journal › Published meeting abstract
-
Mark
Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions
(
- Contribution to journal › Article
-
Mark
The pro-FEIBA study: prophylactic dosing of Factor Eight Inhibitor Bypassing Activity (FEIBA) reduces bleeding frequency in haemophilia a patients with inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
Optimizing patient therapy - optimal dosing: when is enough enough?
(
- Contribution to journal › Article
-
Mark
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
(
- Contribution to journal › Article
-
Mark
Haematuria and hypertension in haemophilia - the H3 study
(
- Contribution to journal › Published meeting abstract
-
Mark
Bone density and health-related quality of life in adult patients with severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Osteoporosis: a real problem in haemophilia?
(
- Contribution to journal › Published meeting abstract
-
Mark
Thrombotic occlusion of all left coronary branches in a young woman with severe ulcerative colitis
2011) In ISRN Cardiology(
- Contribution to journal › Letter
-
Mark
Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
(
- Contribution to journal › Article
-
Mark
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
(
- Contribution to journal › Article
-
Mark
Ovanliga ärftliga former av blödarsjuka. Blödningssymtom, familjehistoria och laboratorieanalyser ger diagnosen.
(
- Contribution to journal › Article
-
Mark
Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: A subgroup analysis from the AURICULA registry in Sweden.
(
- Contribution to journal › Article
-
Mark
Recommendations for assessment, monitoring and follow-up of patients with haemophilia.
2011) In Haemophilia(
- Contribution to journal › Article
-
Mark
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
(
- Contribution to journal › Article
-
Mark
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
(
- Contribution to journal › Article
-
Mark
Importance of rapid bleeding control in haemophilia complicated by inhibitors.
(
- Contribution to journal › Article
-
Mark
When von Willebrand disease comes into age - A matter of change?
(
- Contribution to journal › Article
-
Mark
Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
The Swedish version of the Haemophilia Activity List.
(
- Contribution to journal › Article
- 2010
-
Mark
Clinical probability assessment and biochemical markers in the diagnosis of deep vein thrombosis
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Treatment of Mesenteric Vein Thrombosis
(
- Contribution to journal › Article
-
Mark
Cellular Factor Xiii And Peptidylarginine Deiminase-Catalysed Citrullination In Rheumatoid Arthritis
2010) 30th European Workshop for Rheumatology Research In Annals of the Rheumatic Diseases 69(Suppl. 2).(
- Contribution to journal › Published meeting abstract
-
Mark
Thrombin Generation Testing for Monitoring Hemophilia Treatment: A Clinical Perspective
(
- Contribution to journal › Article
-
Mark
Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group
(
- Contribution to journal › Published meeting abstract
-
Mark
Von Willebrand disease prophylaxis network
(
- Contribution to journal › Published meeting abstract
-
Mark
Clinical issues in inhibitors
(
- Contribution to journal › Scientific review
-
Mark
The role of prophylaxis in bleeding disorders
(
- Contribution to journal › Scientific review
-
Mark
Treatment of the critically ill patient with protein C: Is it worth the cost?
(
- Contribution to journal › Article
-
Mark
The combination of Octaplex (R) and Octanate (R) restores thrombin generation capacity in FVIII inhibitor plasma in-vitro
(
- Contribution to journal › Published meeting abstract
-
Mark
FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
(
- Contribution to journal › Article
-
Mark
The necessity of having FVIII in VWF concentrates
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.400-400(
- Contribution to journal › Published meeting abstract
-
Mark
The diagnostic performance of APC-PCI complex determination compared to d-dimer in the diagnosis of deep vein thrombosis
(
- Contribution to journal › Article
-
Mark
A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.31-31(
- Contribution to journal › Published meeting abstract
-
Mark
A retrospective study: of Octaplex (R) in the treatment of bleeding in patients with haemophilia A complicated by inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
Influence of the pre-analytical specimen storage conditions on thrombin generation assay
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.45-45(
- Contribution to journal › Published meeting abstract
-
Mark
Differential response to bypassing agents
(
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Network activities were initiated in December, 2009, and will extend over the next five years. von Willebrand disease prophylaxis network
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients Results From a Prospective Registry of European Hemophilia B Patients
(
- Contribution to journal › Published meeting abstract
-
Mark
F8 haplotype and recombinant product use in the Hemophilia Inhibitor Genetics Study (HIGS)
(
- Contribution to journal › Published meeting abstract
-
Mark
Prophylactic Dosing of Anti Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors Results of the Pro FEIBA Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Prophylaxis in von Willebrand disease
(
- Contribution to journal › Published meeting abstract
-
Mark
Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate haemophilia A: first results from the INSIGHT study
(
- Contribution to journal › Published meeting abstract
-
Mark
Mild haemophilia in Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
(
- Contribution to journal › Article